Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours
Article in Cancer Immunology, Immunotherapy (March 2024)
The most recent citing publications are shown below. View all 70 publications that cite this research output on Dimensions.
Article in Cancer Immunology, Immunotherapy (March 2024)
Article in ESMO Open (February 2024)
Article in Nature Communications (February 2024)